Company: NOTV
Filing Date: 2025-02-06
Form Type: 10-Q
Source: 0001628280-25-004178
Chunk: 5

Company: Inotiv, Inc.
Filing Date: 2025-02-06
Form: 10-Q
Item: Part I, Item 1
Chunk 5
---
 of common shares27,524 — Other financing activities, net(708)(2,230)Net cash provided by (used in) financing activities26,125 (2,921)  Effect of exchange rate changes on cash and cash equivalents(558)18 Net increase (decrease) in cash and cash equivalents16,611 (13,491)Cash and cash equivalents at beginning of period21,432 35,492 Cash and cash equivalents at end of period$38,043 $22,001   Supplemental disclosure of cash flow information:  Cash paid for interest$10,888 $11,068 Income taxes paid, net$271 $298 

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

8

Index to Unaudited Condensed Consolidated Financial Statements

PageNOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS101. DESCRIPTION OF THE BUSINESS AND BASIS OF PRESENTATION 102. REVENUE FROM CONTRACTS WITH CLIENTS133. SEGMENT AND GEOGRAPHIC INFORMATION144. DEBT165. SUPPLEMENTAL BALANCE SHEET INFORMATION246. DEFINED BENEFIT PLAN257. OTHER OPERATING EXPENSE268. RESTRUCTURING AND ASSETS HELD FOR SALE269. LEASES 2710. EQUITY, STOCK-BASED COMPENSATION AND LOSS PER SHARE2811. INCOME TAXES3012. CONTINGENCIES AND COMMITMENTS31

9

INOTIV, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in thousands except share amounts, unless otherwise indicated)

(unaudited)

1.    DESCRIPTION OF THE BUSINESS AND BASIS OF PRESENTATION

Inotiv, Inc. and its subsidiaries (“we,” “our,” “us,” the “Company,” and “Inotiv”) comprise a leading contract research organization (“CRO”) dedicated to providing nonclinical and analytical drug discovery and development services primarily to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries as well as academia and government clients. Our products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development, all while increasing efficiency, improving data, and reducing the cost of discovering and taking new drugs and medical devices to market. Inotiv is committed to supporting discovery and development objectives as